Resampling Fragility in the MUTTON-HF Randomized Clinical Trial of an Indigenous Food Is Medicine Intervention

Authors

  • Thomas F. Heston Department of Family Medicine, University of Washington, Seattle, USA; Department of Medical Education and Clinical Sciences, Elson S. Floyd College of Medicine, Washington State University, Spokane, USA https://orcid.org/0000-0002-5655-2512

DOI:

https://doi.org/10.5281/zenodo.22784136

Keywords:

resampling fragility, perturbation fragility, statistical fragility, global fragility quotient, complete statistical evidence, heart failure, food is medicine

Abstract

Statistical fragility is not a single quantity. Resampling fragility estimates the probability that a trial's significance classification would reverse in a new sample of the same size, while perturbation fragility measures the minimum change to the recorded data that reverses the classification in the observed table. The primary endpoint of the Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure (MUTTON-HF) randomized clinical trial carries a resampling fragility of 0.38 under a within-arm binomial replication model, and a global fragility quotient of 0.0097 (unstable). These fragility metrics indicate that the significance classification behind this clinically promising result is easily reversed and therefore warrants cautious interpretation.

References

1. Carter RE, McKie PM, Storlie CB. The Fragility Index: a P-value in sheep’s clothing? Eur Heart J. 2017;38: 346–348. doi:10.1093/eurheartj/ehw495

2. Li J, O’Connell PJ. The Fragility Index: The P-Value by Another Name? Transplantation. 2022;106: 239. doi:10.1097/TP.0000000000003806

3. Eberly LA, George C, Sandman S, Bex D, Jones K, Yazzie A, et al. An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial. JAMA Intern Med. 2026;186: 1077. doi:10.1001/jamainternmed.2026.2879

4. Wasserstein R, Lazar N. The ASA Statement on p -Values: Context, Process, and Purpose. Am Stat. 2016;70: 129–133. doi:10.1080/00031305.2016.1154108

5. Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67: 622–628. doi:10.1016/j.jclinepi.2013.10.019

6. Heston TF. Resampling Fragility, Perturbation Fragility, and Why the Global Fragility Index Is Not a P-Value in Disguise. Internet Med J. 2026;1: e22059146. doi:10.5281/zenodo.22059146

7. Heston TF. Significance, Fragility, and Robustness in Clinical Trials: Stratifying Statistical Evidence. Cureus. 2025;17. doi:10.7759/cureus.100494

8. Van Zwet EW, Goodman SN. How large should the next study be? Predictive power and sample size requirements for replication studies. Stat Med. 2022;41: 3090–3101. doi:10.1002/sim.9406

Downloads

Published

2026-09-16

How to Cite

Heston, T. F. (2026). Resampling Fragility in the MUTTON-HF Randomized Clinical Trial of an Indigenous Food Is Medicine Intervention. Internet Medical Journal, 1(1), e22784136. https://doi.org/10.5281/zenodo.22784136

Issue

Section

Perspectives